ResMed Shares Sink 3.5% as Institutional Selling and GLP-1 Headwinds Rattle Investors
ResMed Inc. (RMD) shares tumbled 3.49% to $251.69 on Tuesday, significantly underperforming a rising S&P 500 as the medical device leader faces a dual threat from institutional divestment and accelerating competition from weight-loss medications. The sharp divergence comes as major funds report significant stake reductions and the FDA's latest approval for Eli Lilly’s tirzepatide further clouds the long-term outlook for traditional sleep apnea therapy.
Institutional Exit Triggers Bearish Sentiment
ResMed (RMD) became a focal point of selling pressure during Tuesday's session after regulatory filings revealed a significant retreat by institutional investors. Most notably, LGT Capital Partners LTD reported a massive 66% reduction in its position, selling over 267,000 shares. This divestment, disclosed in a Form 13F filing, has raised concerns among market participants about the conviction of long-term holders in the medical technology giant. ResMed now accounts for just 1.8% of the fund's holdings, a sharp drop that suggests a strategic shift away from the sleep-disordered breathing market.
GLP-1 "KwikPen" Approval Intensifies Competition
The selling pressure was exacerbated by news from the pharmaceutical sector. On February 23, the FDA approved a monthly KwikPen delivery option for Eli Lilly’s tirzepatide (Zepbound), making the blockbuster weight-loss drug significantly more accessible and convenient for patients. This development is a direct headwind for ResMed, as clinical data from the SURMOUNT-OSA trials has already demonstrated that tirzepatide can lead to disease resolution in up to 51.5% of patients with moderate-to-severe obstructive sleep apnea (OSA). By lowering the barrier to entry for pharmaceutical intervention, the KwikPen approval threatens to accelerate the migration of patients away from traditional continuous positive airway pressure (CPAP) machines.
Technical Breakdown and Sector Divergence
From a technical perspective, today's move is particularly damaging. RMD shares broke below their 50-day moving average of $253.32, a level that had previously served as a reliable support zone. The stock is now testing its 200-day moving average near $261.72 from the underside, a bearish signal that often precedes further consolidation. While the broader S&P 500 (SPY) gained 0.57% today, ResMed’s 4.06% relative underperformance highlights a sector-specific rotation out of medical hardware and into high-growth biopharma.
Competitive Pressure from a Recovering Philips
Adding to ResMed's woes is the continued reintegration of Koninklijke Philips (PHG) into the U.S. market. Following years of recall-related absence, Philips is aggressively reclaiming market share with its new generation of sleep therapy devices. Analysts note that ResMed’s period of uncontested dominance is effectively over, forcing the company to compete on price and innovation at a time when the total addressable market is being challenged by GLP-1 medications. While ResMed reported a strong Q2 earnings beat in late January with an EPS of $2.81, the market is currently prioritizing long-term structural risks over short-term financial performance.
Key Takeaways
- Institutional selling led by LGT Capital Partners, which slashed its RMD position by 66%, triggered a wave of divestment.
- The FDA's approval of the tirzepatide KwikPen increases the competitive threat from weight-loss drugs to the CPAP market.
- ResMed broke below its 50-day moving average of $253.32, signaling a potential shift in the medium-term technical trend.
- Renewed competition from Philips Respironics is ending ResMed's multi-year period of market share expansion.